Dentsply Sirona (NASDAQ:XRAY) Stock, Quote.Headers.trade-ideas

Dentsply Sirona

Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).

European,Young,Woman,Smiling,While,Looking,At,Mirror,In,Dental

Analyst Color

Earnings

Equities

News

Guidance

Markets

Analyst Ratings

Movers

General

PDCO

XRAY

Dentsply Sirona misses Q2 earnings, announces restructuring amid weak demand.

Dentsply Sirona Misses Q2 Targets - Plans Restructuring Plan Amid Weak Demand

Medical,Examination,And,Healthcare,Business,Graph,,,Health,Insurance,,Health

Long Ideas

Insider Trades

Pre-Market Outlook

Trading Ideas

CRGX

WTFC

$4M Bet On This Health Care Stock? Check Out These 3 Stocks Insiders Are Buying

Beating,Estimates,Wall,Street,Prices,Stock,Market,Tickers,3d,Illustation

Eurozone

Commodities

Intraday Update

ASPN

CVNA

FSLY

VSTS

XPEL

Nasdaq Gains Over 200 Points; Dentsply Sirona Shares Fall After Q1 Results

Dentsply Sirona Inc

<p>Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $32.0, a high estimate of $38.00, and a low estimate of $27.00. Experiencing a 5.19% decline, the current average is now lower than the previous average price target of $33.75. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1726848086_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Dentsply Sirona. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$36.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jeffrey Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Dentsply Sirona. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dentsply Sirona compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Dentsply Sirona's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Dentsply Sirona's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XRAY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dentsply Sirona analyst ratings.</strong></a></p>
<h2>Delving into Dentsply Sirona's Background</h2>
<p>Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).</p>
<h3>Breaking Down Dentsply Sirona's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Revenue Challenges:</strong> Dentsply Sirona's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-4.28%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Dentsply Sirona's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-0.41%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-0.13%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-0.06%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Dentsply Sirona's debt-to-equity ratio is below the industry average at <strong>0.72</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Expectations For Dentsply Sirona's Future

<p>Barrington Research  analyst Michael Petusky   maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Outperform and maintains $36 price target.</p>


Price Target

Barrington Research Maintains Outperform on Dentsply Sirona, Maintains $36 Price Target

WIIM

Dentsply Sirona shares are trading lower. The company announced the resignation of its CFO and executive vice president and will begin searching for a replacement immediately.

<p>Ratings for Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Dentsply Sirona, revealing an average target of $31.43, a high estimate of $38.00, and a low estimate of $27.00. A 5.98% drop is evident in the current average compared to the previous average price target of $33.43. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1724169623_0_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of Dentsply Sirona among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$34.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Jeffrey Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$31.00</td>
<td>$33.00</td>
</tr>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$35.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dentsply Sirona. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Dentsply Sirona compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Dentsply Sirona's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Dentsply Sirona's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XRAY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dentsply Sirona analyst ratings.</strong></a></p>
<h2>About Dentsply Sirona</h2>
<p>Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).</p>
<h3>Dentsply Sirona's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Dentsply Sirona's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately <strong>-4.28%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Dentsply Sirona's net margin excels beyond industry benchmarks, reaching <strong>-0.41%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-0.13%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Dentsply Sirona's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>-0.06%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.72</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Critical Insights From Dentsply Sirona Analyst Ratings: What You Need To Know

<p>Needham  analyst David Saxon   reiterates Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Buy and maintains $34 price target.</p>


Reiteration

Needham Reiterates Buy on Dentsply Sirona, Maintains $34 Price Target

Health Care

Management

Dentsply Sirona Announced That Executive Vice President And CFO Glenn Coleman Will Resign Effective November 7; The Company Has Initiated A Search Process To Identify Its Next CFO

<p>Needham  analyst David Saxon   maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Buy and lowers the price target from $36 to $34.</p>


Needham Maintains Buy on Dentsply Sirona, Lowers Price Target to $34

<p><strong>DENTSPLY SIRONA Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading higher on Wednesday.</a></p>
<p>The company reported second-quarter adjusted earnings per share of 49 cents, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/07/g40061613/dentsply-sirona-reports-second-quarter-2024-results-and-announces-second-phase-of-transformation" rel="noreferrer noopener">missing the street view of 50 cents,</a> and quarterly sales of $984 million, missing the <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">analyst consensus of $995.66 million</a>.</p>
<p>According to <strong>William Blair </strong>analyst Brandon Vazquez, largest miss came from Connected Technology Solutions (equipment), <a target="_blank" href="https://www.benzinga.com/quote/XRAY/analyst-ratings" rel="noreferrer noopener">which was down 16% on an organic basis.</a></p>
<p>&#8220;Our second quarter results were unfavorably impacted by lower demand in our Connected Technology Solutions segment due to continued macroeconomic and competitive pressure,&#8221; said Simon Campion, President and Chief Executive Officer.</p>
<p><strong>Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/asia/24/07/40062747/asia-markets-up-europe-opens-higher-crude-advances-2-6-global-markets-today-while-us-slept" rel="noreferrer noopener">Asia Markets Up, Europe Opens Higher, Crude Advances 2.6% &#8211; Global Markets Today While US Slept</a></strong></p>
<p>In the second quarter of 2024, the company repurchased $150 million in stock and plans to buy back an additional $100 million in the third quarter.</p>
<p>In his research note, Vazuez adds that end-markets remain challenging, and Dentsply is not immune to headwinds, but the company has levers to pull to help outperform peers (costsavings, unique products, and share buybacks).</p>
<p>The company had $279 million of cash and cash equivalents as of June-end.</p>
<p>The company highlighted its second phase of transformation, where it aims to cut annual operating expenses by $80 million to $100 million over 12 to 18 months.</p>
<p>Dentsply Sirona is also projecting $40 million-$50 million in non-recurring charges to be expensed in 2024 and 2025.</p>
<p>The restructuring plan anticipates a net reduction in the company's global workforce of approximately 2% to 4%.</p>
<p>&#8220;The second phase of our transformation allows us to both fund reinvestment in our business to better position us to drive profitable growth and contribute to our 2026 adjusted EPS target,&#8221; Campion added. As part of this second phase, Andreas Frank, Executive Vice President and Chief Business Officer, will leave Dentsply Sirona in October.</p>
<p><strong>Outlook:</strong> Dentsply Sirona forecasts 2024 sales of $3.86 billion to $3.90 billion, below the prior view of $3.91 billion&nbsp;to&nbsp;$3.97 billion. The outlook is also below the consensus of $3.93 billion, with organic growth expected to be flat or down 1%.</p>
<p>The company anticipates adjusted EPS of $1.96 to $2.02, slightly below the consensus of $2.01 and down from the <a target="_blank" href="https://www.benzinga.com//node/38575439" rel="noreferrer noopener">previous range of $2.00 to $2.10.</a></p>
<p>In a regulatory <a target="_blank" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/818479/000081847924000069/xray-20240630.htm" rel="noreferrer noopener">filing</a>, the company disclosed that in July 2024, it delivered a one-year notice of non-renewal in connection with its non-exclusive distribution agreements with <strong>Patterson Companies, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDCO#NASDAQ">PDCO</a>) for the distribution of dental equipment in the U.S. and Canada.</p>
<p>It is anticipated that Patterson will continue to be one of the company's two largest distributors as a percentage of its global revenue during the one-year notice period.</p>
<p>The company intends to engage in discussions for new distribution agreements with Patterson. However, failure to successfully renegotiate the distribution agreements or secure potential new agreements with another distributor could adversely affect its business, operating results, and financial condition.</p>
<p><strong>Price Action: </strong>XRAY shares are trading higher by 3.02% to $27.59 at last check Wednesday.</p>
<p><strong><em>Disclaimer</em></strong><em>: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.</em></p>
<p><em>Photo via Shutterstock</em></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/07/40061267/asml-shares-surge-over-7-as-team-biden-plans-to-exempt-allies-from-new-rule-on-foreign-chip-equipmen" target="_blank" rel="noreferrer noopener">ASML Shares Surge Over 7% As Team Biden Plans To Exempt Allies From New Rule On Foreign Chip Equipment Export To China</a></strong></li>
</ul>


In July 2024, Dentsply Sirona Issued A 1-Year Notice To Not Renew Its Distribution Agreements With Patterson Companies, For Dental Equipment In The U.S. And Canada, Planning To Negotiate New Agreements, A Failure To Renegotiate Posing A Potential Material Adverse Effect On Its Business; Co Says Not Expecting A Charge Against Earnings For The Non-Renewal

Buybacks

Dentsply Sirona Expects To Repurchase $100M Of Its Common Stock In Q3 2024

Dentsply Sirona Expects 2024 Sales Of $3.86B-$3.90B (Vs. Consensus Of $3.931B), Down (1%) To Flat On An Organic Basis (Previously Flat To Up 1.5%), Expects Adjusted EPS Of $1.96-$2.02 (Vs. Consensus Of $2.01) (Previously $2.00-$2.10)

Dentsply Sirona shares are trading lower after the company reported worse-than-expected Q2 financial results.

Dentsply Sirona Initiates The Second Phase Of Restructuring Plan, The Company Expects To Incur $40M-$50M In Non-recurring Charges, Which Will Be Expensed In 2024 And 2025. $80M-$100M Annualized Cost Savings Expected Over Next 12 To 18 Months

Dentsply Sirona Q2 2024 Adj. EPS $0.49 Misses $0.50 Estimate, Sales $984.000M Miss $995.666M Estimate

<p>Baird  analyst Jeffrey Johnson   maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Neutral and lowers the price target from $33 to $31.</p>


Baird Maintains Neutral on Dentsply Sirona, Lowers Price Target to $31

<p>In the preceding three months, 10 analysts have released ratings for Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $32.5, a high estimate of $38.00, and a low estimate of $27.00. Observing a downward trend, the current average is 9.22% lower than the prior average price target of $35.80. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1721314865_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>A clear picture of Dentsply Sirona's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jonathan Block</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$27.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Nathan Rich</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Jeffrey Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dentsply Sirona. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dentsply Sirona compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Dentsply Sirona's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Dentsply Sirona's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XRAY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dentsply Sirona analyst ratings.</strong></a></p>
<h2>About Dentsply Sirona</h2>
<p>Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).</p>
<h3>A Deep Dive into Dentsply Sirona's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.</p>
<p><strong>Revenue Growth:</strong> Dentsply Sirona's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately <strong>-2.56%</strong>. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Dentsply Sirona's net margin excels beyond industry benchmarks, reaching <strong>1.89%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Dentsply Sirona's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>0.55%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> Dentsply Sirona's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.25%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Dentsply Sirona's debt-to-equity ratio is below the industry average at <strong>0.68</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Glimpse Into The Expert Outlook On Dentsply Sirona Through 10 Analysts

<p>Stifel  analyst Jonathan Block   maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Hold and lowers the price target from $30 to $28.</p>


Stifel Maintains Hold on Dentsply Sirona, Lowers Price Target to $28

<p>Evercore ISI Group  analyst Elizabeth Anderson   maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Outperform and lowers the price target from $28 to $27.</p>


Evercore ISI Group Maintains Outperform on Dentsply Sirona, Lowers Price Target to $27

<p>Barrington Research  analyst Michael Petusky   maintains Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>) with a Outperform and maintains $38 price target.</p>


Barrington Research Maintains Outperform on Dentsply Sirona, Maintains $38 Price Target

<p>During the last three months, 8 analysts shared their evaluations of Dentsply Sirona (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRAY#NASDAQ">XRAY</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $34.12, with a high estimate of $41.00 and a low estimate of $28.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.93%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1719345750_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The perception of Dentsply Sirona by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Nathan Rich</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$30.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Elizabeth Anderson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$35.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$38.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Jeffrey Johnson</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$33.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Michael Petusky</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dentsply Sirona. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dentsply Sirona compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Dentsply Sirona's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Dentsply Sirona's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/XRAY/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dentsply Sirona analyst ratings.</strong></a></p>
<h2>Get to Know Dentsply Sirona Better</h2>
<p>Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).</p>
<h3>Dentsply Sirona: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Dentsply Sirona faced challenges, resulting in a decline of approximately <strong>-2.56%</strong> in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Dentsply Sirona's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>1.89%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Dentsply Sirona's ROE excels beyond industry benchmarks, reaching <strong>0.55%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>0.25%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.68</strong>, Dentsply Sirona adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Evaluating Dentsply Sirona: Insights From 8 Financial Analysts

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on DENTSPLY SIRONA (XRAY – Research Report), Teva Pha...

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (XRAY), Teva Pharmaceutical (TEVA) and Option Care Health (OPCH)

Dentsply Sirona CFO Glenn Coleman to resign

Premier appoints Coleman as chief administrative and financial officer

DENTSPLY SIRONA (XRAY) has provided an update. Glenn G. Coleman is stepping down as Executive Vice President, Chief Financial Officer, and principa...

DENTSPLY SIRONA Announces CFO Glenn Coleman's Departure

DENTSPLY SIRONA (XRAY – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst David Saxon from Nee...

Buy Rating Affirmed Despite CFO Departure: Confidence in DENTSPLY SIRONA's Strategic Initiatives and Growth Prospects

Leerink Partners analyst Michael Cherny has maintained their bullish stance on XRAY stock, giving a Buy rating on August 20. Michael Cherny has giv...

DENTSPLY SIRONA: A Buy Rating Amid CFO Transition and Robust Growth Targets

Executive reshuffles: PFG, IRDM, AYRO and XRAY Companies in focus

Tracking Al Gore's Generation Investment Management Portfolio - Q2 2024 Update

Leerink Partners analyst Michael Cherny reiterated a Buy rating on DENTSPLY SIRONA (XRAY – Research Report) yesterday. The company's shares closed ...

DENTSPLY SIRONA (XRAY) Receives a Buy from Leerink Partners

In a report released today, Michael Petusky from Barrington maintained a Buy rating on DENTSPLY SIRONA (XRAY – Research Report), with a price targe...

DENTSPLY SIRONA: Poised for Growth with Strategic Initiatives and Strong FY/26 Targets—A Buy Recommendation

AMZN

AYRO

CBRE

CLVT

FRSH

HSIC

IRDM

MELI

MSFT

NTNX

OPCH

PINC

RELY

SCHW

SOPH

TEVA

TOST

TRMB

TSMWF

TWLO

TYGO

WDAY

Press Releases

DENTSPLY SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Dentsply Sirona Inc. (NASDAQ: XRAY) and Encourages Long-Term XRAY Shareholders to Contact the Firm

NASDAQ: XRAY Lawsuit Update: Investors who lost money with shares of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) should contact the the Shareholders Foundation

XRAY Investors Have the Opportunity to Join Investigation of DENTSPLY SIRONA Inc. with the Schall Law Firm

Dentsply Sirona to Host Second Quarter Conference Call on July 31st

Legal

SHAREHOLDER ALERT: Morris Kandinov Investigating XRAY, ENVX, SHC and HLLY; Shareholders are Encouraged to Contact the Firm

Dentsply Sirona Reports Second Quarter 2024 Results and Announces Second Phase of Transformation

Dentsply Sirona Initiates Search for New CFO

Dentsply Sirona to Participate in Upcoming Investor Conferences

Dentsply Sirona presents Primescan® 2 powered by DS Core: The first cloud-native intraoral scanning solution

Kaskela Law LLC Announces Shareholder Investigation of Dentsply Sirona Inc. (NASDAQ: XRAY) and Encourages Long-Term XRAY Shareholders to Contact the Firm

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Dentsply Sirona

Dentsply Sirona (XRAY) Forecast

Dentsply Sirona (NASDAQ:XRAY) Stock, Quote.Headers.trade-ideas